You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Epithelial Alarmins: A New Paradigm in Severe Asthma and Emerging Treatments

  • Authors: Eileen Wang, MD, MPH (Program Co-Chair); Michael E. Wechsler, MD, MMSc (Program Co-Chair)
  • CME Released: 6/30/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/30/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

Primary target audiences: This activity is intended for pulmonologists and allergists; Secondary target audiences: Nurse practitioners and physician assistants in relevant specialties.

The goal of this educational activity is to improve the competence and knowledge of allergists, pulmonologists, and advance practice providers as they focus on the roles of epithelial alarmins, including TSLP, IL-33, and IL-25, as upstream mediators of the asthma inflammatory response and airway hyperresponsiveness. The growing arsenal of promising treatments for severe asthma signals new possibilities for improved quality of life for patients. Clinicians must possess a strong understanding of the complexities and nuances of these new therapies, so they can apply their knowledge to improve patient outcomes most powerfully.

Upon completion of this activity, participants should be able to:

  1. Describe the role of the respiratory epithelium in asthma development and progression.
  2. Define the epithelial alarmins and their impact on T2 and non-T2 airway inflammation, remodeling, and hyperresponsiveness in severe asthma.
  3. Evaluate the results of clinical trials of emerging therapies that target the epithelial alarmins in severe asthma.
  4. Match clinical characteristics and phenotypes to treatment targets.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

 

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

 

Unlabeled and Investigational Usage

 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

 

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

 

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

 

Disclaimer Statement

 

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

 

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

 

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.


Faculty

  • Eileen Wang, MD, MPH

    Associate Professor
    Division of Allergy & Clinical Immunology
    Department of Medicine
    National Jewish Health
    Denver, Colorado

    Disclosures

    Disclosure: Eileen Wang, MD, MPH, has the following relevant financial relationships:
    Served as advisor for: AstraZeneca; GlaxoSmithKline
    Served as a speaker for: AstraZeneca
    Served as investigator for: AstraZeneca; Genentech; GlaxoSmithKline; Sanofi

  • Michael E. Wechsler, MD, MMSc

    Director, The Cohen Family Asthma Institute
    Professor of Medicine
    Department of Medicine
    Division of Pulmonary, Critical Care & Sleep Medicine
    National Jewish Health
    Denver, Colorado

    Disclosures

    Disclosure: Michael E. Wechsler, MD, MMSc, has the following relevant financial relationships:  
    Served as consultant for: Amgen; AstraZeneca; Genentech; Genzyme; GlaxoSmithKline; Sanofi Regeneron  
    Served as an investigator for: AstraZeneca; GlaxoSmithKline 

Additional Planners/Reviewers

  • Harold Nelson, MD

    Disclosures

    Harold Nelson, MD has the following relevant financial relationships:
    Served on the Data Safety Monitoring Board for AstraZeneca.

The following planners/reviewers declare that they do not have any relevant financial relationships:
Meghan Brenner, MA; Elyce Bowron, Med; Mandy Comeau; Andrea Harshman, MHA, CHCP, CMP-HC; Michael Mohning, MD

 

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.


Accreditation Statements

This activity is provided by the National Jewish Health.

    For Physicians

  • National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Epithelial Alarmins: A New Paradigm in Severe Asthma and Emerging Treatments

Authors: Eileen Wang, MD, MPH (Program Co-Chair); Michael E. Wechsler, MD, MMSc (Program Co-Chair)Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 6/30/2022

Valid for credit through: 6/30/2023, 11:59 PM EST

processing....

Pre-Assessment

Before you begin, please answer the questions in this brief questionnaire.

  • Print